Pegasys Gets HIV Co-Infection Claim; Market Expansion Moves Forward
Executive Summary
Roche is looking to a new chronic hepatitis C indication for Pegasys in patients co-infected with HIV to expand its hepatitis market penetration
You may also be interested in...
Pegasys Adds Hepatitis B Indication, But Not Superiority Claim Over Epivir
Roche is highlighting Pegasys' limited duration of treatment relative to other hepatitis B therapies following approval of the supplemental indication
Pegasys Adds Hepatitis B Indication, But Not Superiority Claim Over Epivir
Roche is highlighting Pegasys' limited duration of treatment relative to other hepatitis B therapies following approval of the supplemental indication
Pegasys Market Position Secure, Roche Says; Dismisses PEG-Intron Data
Roche expects to have firmly established its leadership position in the hepatitis C market with Pegasys by the time Schering-Plough publishes the results from its ongoing head-to-head study versus PEG-Intron